Dollar, money

COVID-19 Boosts PCR Diagnostics Market, to Exceed $6 Billion by 2030

By MedTech Intelligence Staff
Dollar, money

The PCR and real-time PCR molecular diagnostics was valued at $4 billion in 2019.

As manufacturers continue to invest more in rapid testing, the PCR and real-time PCR molecular diagnostics market are expected to achieve growth over the long term. The market was valued at $4 billion last year and boosted by COVID-19 and emergency use authorizations, it is anticipated to exceed $6 billion by 2030, according to a recent report by research firm Fact.MR.. Thus far North America is leading regional markets for the technology and is followed by Europe. Other diagnostic segments expected to grow include oncology, which will be driven by more patients an investment in modernizing healthcare centers.

Key players in the PCR and real-time PCR molecular diagnostics market include Abbott Laboratories, Elekta AB Bio-Rad Laboratories Inc., bioMerieux SA, Danaher Corporation, Thermo Fisher Scientific Inc., Becton, Dickinson and Company, F.Hoffmann-La Roche Ltd., Qiagen NV, Hologic Inc, Grifols SA, Genomic Health, and Seegene Inc.

Related Articles

  • Andrew Lacy

    The key priority for any healthcare system should be the well-being of patients. At present, the U.S. healthcare system is failing to target low-hanging fruit that could help drive better results for patients, and—by catching illnesses earlier—ultimately lower the cost…

  • Doug Folsom, TRIMEDX

    The omicron variant of the coronavirus has made clear that the impact of the pandemic is far from over, particularly for health systems and hospitals. The ongoing need to limit close contact between providers and patients means technology will continue…

  • Sanobar Syed

    Market research and forecasting help ensure that you are investing in a device or drug that is needed and will be well received. In this article, Sanobar Syed, Associate Director of Forecasting, Market Insights and Strategies, BeiGene, highlights strategies to…

  • Daniel Lace

    “We are honored to have Dr. Lace, who is widely recognized as one of the industry’s most trusted reimbursement experts, leading our new division. He will also support all our services as our CMO.”

About The Author

MedTech Intelligence